Family history screening program for BRCA-related cancers in rural clinics

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates an adapted family history screening program aimed at increasing the uptake of genetic screening for BRCA-associated cancers among women in rural public health clinics in Southwest Georgia. The program, known as GA CORE, will be modified to enhance its reach and effectiveness, utilizing a multi-site, cluster randomized controlled trial design. Participants will engage in stakeholder meetings, discussions, and surveys to inform the adaptation process, while the effectiveness of the new program will be compared to the existing standard care approach. The study will also assess implementation factors using the RE-AIM framework to ensure sustainability and effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* AIM 1 STAKEHOLDER ADVISORY COMMITTEE: 10 stakeholders representing three constituencies: state cancer control leaders (n=2), participating public health district champions (n=4) (i.e., administrative directors, nurses, clinic staff) and patients (n=4) (i.e., women, age 25 and older who receive their care in the Southwest district)
* AIM 1 DISCUSSION FORUM: 25 years or older
* AIM 1 DISCUSSION FORUM: Women
* AIM 1 DISCUSSION FORUM: English-speaker
* AIM 1 DISCUSSION FORUM: Have completed family history screening during the first 3 months of the project at one of 14 public health clinics in Southwest district
* AIM 1 ORGANIZATIONAL STAKEHOLDER INTERVIEW: Organizational stakeholders (i.e., medical directors, nurses, and clinic staff) at the 14 clinic sites in Southwest district
* AIM 2: Women
* AIM 2: Ages 25 and older
* AIM 2: Who can read English
* AIM 2: Have ever been seen in Women's Health Section through one of participating public health clinics in Southwest district
* AIM 3 POST-INTERVENTION INTERVIEW: Participants from aim 2, regardless of whether they completed the recommended genetic services or not (e.g. complete telegenetic session or genetic testing)
* AIM 3 WORKSHOP DISCUSSION: Medical and administrative directors, nurses, and clinic staff from the six participating clinic sites

Where it's running

• Emory University Hospital/Winship Cancer Institute
  Atlanta, Georgia, United States Recruiting

Study contacts

• Principal investigator: Yue Guan — Emory University Hospital/Winship Cancer Institute
• Study coordinator: Yue Guan, PhD
• Email: yue.guan@emory.edu
• Phone: 404-712-1671

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• EHR-based approach to boost HBOC genetic testing in at-risk women

  A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.

  Recruiting Columbia University · New York, New York · NCT07876349

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• Romiplostim N01 plus ATRA for persistent chemotherapy-induced low platelets after remission from gynecologic, breast, or lung cancer

  This trial tests whether adding ATRA to Romiplostim N01 helps people keep a safe platelet count after finishing chemotherapy for certain cancers.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07586826

• CAIX-targeted 18F-T2 PET/CT imaging in solid tumors

  This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07557225

• Preventive removal or staged removal of fallopian tubes and ovaries for women with hereditary ovarian cancer risk

  This project will test whether removing fallopian tubes now and delaying ovary removal, versus standard full removal or close monitoring, reduces ovarian cancer risk and preserves ovarian function in women with BRCA or similar gene changes.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07532434

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.